The FDA is expected to deliver its decision on the expanded use of Tezspire for treating chronic rhinosinusitis with nasal polyps by October 19, 2025.In a phase III trial, dubbed WAYPOINT, Tezspire significantly reduced nasal congestion, polyp size, and nearly eliminated the need for surgery in patients with chronic rhinosinusitis with nasal polyps.Co-developed by AstraZeneca plc (AZN) and Amgen Inc. (AMGN), Tezspire is already approved for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. The combined sales of Tezspire, recorded by Amgen and AstraZeneca, rose to $826 million in the first half of 2025, from $507 million in the first half of 2024.AMGN closed Friday’s (September 26, 2025) trading at $272.98, up 0.66%.